))
Bexion Pharmaceuticals: Leveraging the Lysosome
Gearchiveerde serie ("Inactieve feed" status)
When?
This feed was archived on April 14, 2023 20:25 (
Why? Inactieve feed status. Onze servers konden geen geldige podcast feed ononderbroken ophalen.
What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.
Manage episode 288956952 series 2448731
Inhoud geleverd door Childhood Cancer Talk Radio Podcasts. Alle podcastinhoud, inclusief afleveringen, afbeeldingen en podcastbeschrijvingen, wordt rechtstreeks geüpload en geleverd door Childhood Cancer Talk Radio Podcasts of hun podcastplatformpartner. Als u denkt dat iemand uw auteursrechtelijk beschermde werk zonder uw toestemming gebruikt, kunt u het hier beschreven proces https://nl.player.fm/legal volgen.
Dr. Ray Takigiku (founder and CEO) and Dr. Richard Curry, Medical Affairs Consultant at Bexion Pharmaceuticals discuss BXQ-350 and the 2 phase II adult clinical trials coming up as well as a phase II for a pediatric brain tumor, a potential breakthrough treatment. Additionally, other clinical and non-clinical data suggest BXQ-350 has activity in CNS diseases, including peripheral neuropathy. Learn about the cutting edge biological paradigm of leveraging the lysosome, as Bexion believes the lysosome is an underexploited cellular orchestrator involved in multiple diseases. BXQ-350 is a first-in-class biologic containing the multifunctional, lysosomal activator protein, Saposin C and a phosphatidylserine.
…
continue reading
263 afleveringen
Delen
